1-244835755-A-G
Variant summary
Our verdict is Pathogenic. Variant got 13 ACMG points: 13P and 0B. PM1PM2PP3PP5_Very_Strong
The NM_198076.6(COX20):c.41A>G(p.Lys14Arg) variant causes a missense, splice region change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000871 in 1,228,692 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_198076.6 missense, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 13 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
COX20 | NM_198076.6 | c.41A>G | p.Lys14Arg | missense_variant, splice_region_variant | 1/4 | ENST00000411948.7 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
COX20 | ENST00000411948.7 | c.41A>G | p.Lys14Arg | missense_variant, splice_region_variant | 1/4 | 1 | NM_198076.6 | P1 | |
COX20 | ENST00000391839.6 | n.100A>G | splice_region_variant, non_coding_transcript_exon_variant | 1/3 | 1 | ||||
COX20 | ENST00000366528.3 | c.41A>G | p.Lys14Arg | missense_variant, splice_region_variant | 1/5 | 2 | |||
COX20 | ENST00000498262.1 | n.97A>G | splice_region_variant, non_coding_transcript_exon_variant | 1/4 | 2 |
Frequencies
GnomAD3 genomes AF: 0.0000470 AC: 7AN: 148900Hom.: 0 Cov.: 32
GnomAD4 exome AF: 0.0000926 AC: 100AN: 1079654Hom.: 0 Cov.: 31 AF XY: 0.0000950 AC XY: 49AN XY: 515542
GnomAD4 genome AF: 0.0000470 AC: 7AN: 149038Hom.: 0 Cov.: 32 AF XY: 0.0000275 AC XY: 2AN XY: 72712
ClinVar
Submissions by phenotype
Mitochondrial complex 4 deficiency, nuclear type 11 Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Undiagnosed Diseases Network, NIH | Dec 18, 2020 | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Apr 06, 2023 | - - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 27, 2023 | This sequence change replaces lysine, which is basic and polar, with arginine, which is basic and polar, at codon 14 of the COX20 protein (p.Lys14Arg). This variant is present in population databases (no rsID available, gnomAD 0.006%). This missense change has been observed in individuals with COX20-related neurological disorder (PMID: 30656193, 31079202, 33751098). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 383938). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. Studies have shown that this missense change is associated with altered splicing resulting in unknown protein product impact (PMID: 33751098). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Sep 25, 2023 | Identified in the compound heterozygous state in a patient with sensory-dominant axonal neuropathy and static encephalopathy; discussed that this presentation may represent an expansion of the COX20-related disorders phenotype, but additional studies are warranted (Xu et al., 2019); Published functional studies demonstrate this variant affects the splicing of exon one (Otero et al., 2019); In silico analysis supports that this missense variant does not alter protein structure/function; Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports a deleterious effect on splicing; This variant is associated with the following publications: (PMID: 30656193, 32606554, 33751098, 31079202, 35598585, 35651336, 36136859) - |
COX20-related disorder Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Jan 31, 2023 | The COX20 c.41A>G variant is predicted to result in the amino acid substitution p.Lys14Arg. This variant is located near the end of exon 1 and splicing prediction programs predict a splicing defect at the consensus splice site (Alamut Visual Plus v.1.6.1). This variant has been reported in the compound heterozygous and homozygous states in multiple individuals with with sensory neuropathy and has been documented as a founder variant in the eastern Chinese Han population (Otero et al. 2019. PubMed ID: 30656193; Dong et al. 2021. PubMed ID: 33751098). Functional analysis showed that the variant disrupted proper splicing and lead to decreased protein expression (Otero et al. 2019. PubMed ID: 30656193; Dong et al. 2021. PubMed ID: 33751098). This variant is reported in 0.0054% of alleles in individuals of European (Non-Finnish) descent in gnomAD (http://gnomad.broadinstitute.org/variant/1-244999057-A-G). This variant is interpreted as pathogenic. - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Mar 05, 2024 | The c.41A>G (p.K14R) alteration is located in exon 1 (coding exon 1) of the COX20 gene. This alteration results from an A to G substitution at nucleotide position 41, causing the lysine (K) at amino acid position 14 to be replaced by an arginine (R). Based on data from gnomAD, the G allele has an overall frequency of 0.002% (1/41838) total alleles studied. The highest observed frequency was 0.005% (1/18582) of European (non-Finnish) alleles. This variant has been identified in the homozygous state and in trans with another COX20 variant in individuals with features consistent with COX20-related mitochondrial complex IV deficiency (Chen, 2023; Li, 2022; Ban, 2022; Dong, 2021; Xu, 2019; Otero, 2018). This nucleotide position is highly conserved in available vertebrate species. RNA studies show that this variant causes abnormal splicing (Dong, 2021; Ban, 2022; Li, 2022). Expression and functional studies show significantly decreased levels of COX20 protein as well as reduced enzyme activity and oxygen consumption rate (Otero, 2018; Xu, 2019; Dong, 2021). This missense variant is predicted to be tolerated by in silico analysis. In silico splice site analysis predicts that this nucleotide substitution will weaken the native splice donor site. Based on the available evidence, this alteration is classified as pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at